Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Danicopan Formulations in Healthy Volunteers
NCT04940559Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH) (5 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 1 more. Started Aug 2016; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04940559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940559.